SSSurbhi Singh

Surbhi Singh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Surbhi Singh has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exosomes in Autoimmunity: Mediators of Autoantigen Presentation and Targets for Therapeutic Intervention in Autoimmune Diseases

    by Hailah M. Almohaimeed, Amany I. Almars, Wajnat A. Tounsi, Zuhair M. Mohammedsaleh, Rajashree Panigrahi, Indu Singh, Surbhi Singh, Bikram Dhara, Daniel Ejim Uti

    Exosomes, as integral mediators of cellular communication, have emerged as crucial players in the pathogenesis and potential treatment of autoimmune diseases. This review explores the dual role of exosomes in mediating autoantigen presentation and their impact on immune dysregulation. Exosomes, by virtue of their cargo—comprising proteins, peptides, and nucleic acids—can influence immune tolerance, potentially leading to the breakdown of self-tolerance and the perpetuation of autoimmune responses. They carry and present autoantigens directly to T cells or indirectly via antigen-presenting cells, thereby initiating and sustaining immune reactions characteristic of autoimmune disorders. Furthermore, the review delves into the therapeutic implications of targeting exosomal pathways, discussing strategies such as inhibiting exosome biogenesis, modifying exosomal content, and blocking exosome uptake by immune cells. Such interventions present promising avenues for developing novel treatments aimed at mitigating autoimmune responses. By harnessing the unique properties of exosomes, future research may pave the way for innovative therapeutic strategies that offer more precise and personalized treatment options for patients suffering from autoimmune diseases. Graphical Abstract


  • Molecular Docking and Simulation of Bioactive Molecules from Antiepileptic Plant Extract Presenting Significant Result in in-vivo Study

    by Pankaj Kalita, Chayanika Devi, Preetom Regon, Chadipiralla Kiranmai, Jyothi Srenuka, Rajashree Panigrahi, Indu Singh, Surbhi Singh, Bikram Dhara, Daniel Ejim Uti, et al.

  • Resveratrol in oral cancer: a systematic review of preclinical studies on its anticancer mechanisms and therapeutic potential

    by Bingru Li, Omer Qutaiba B. Allela, Wadhah Hasan Alkhazali, Nasir Vadia, S. Renuka Jyothi, Rajashree Panigrahi, Ashish Singh Chauhan, Surbhi Singh, Malika Akhrorova, Hayder Naji Sameer, et al.

    Objective Oral cancer remains a major global health challenge due to its aggressive nature, high recurrence rates, and limited treatment options. Resveratrol (RV), a naturally occurring polyphenol, has demonstrated promising anticancer properties in various malignancies, including oral cancer. This systematic review aimed to evaluate preclinical evidence on RV’s therapeutic effects in oral cancer, focusing on its mechanisms of apoptosis induction, metastasis inhibition, autophagy regulation, and immune modulation. Methods A systematic review was conducted following PRISMA guidelines, with a comprehensive search in Google Scholar, PubMed, Embase, Scopus, and Web of Science for preclinical studies published up to March 2, 2025. Both in vitro and in vivo studies investigating RV’s effects on oral cancer were included based on predefined inclusion and exclusion criteria. Data extraction was performed independently by multiple researchers, with discrepancies resolved through consensus. Key mechanisms of RV’s anticancer activity, including apoptosis, metastasis suppression, autophagy, and immune regulation, were analyzed. Results Out of 346 studies screened, 19 (four in vivo and 15 in vitro) met the eligibility criteria. RV exhibited potent anticancer effects in a dose- and time-dependent manner, significantly reducing oral cancer cell viability and tumor growth in animal models. Mechanistically, RV induced apoptosis through caspase-3, -7, and -9 activation and modulation of pro-apoptotic (Bax, Bak) and anti-apoptotic (Bcl-2, Bcl-XL) proteins. RV also inhibited key oncogenic pathways, including Akt/mTOR and JAK2/STAT3, thereby suppressing tumor proliferation and immune evasion. Additionally, RV impaired metastatic progression by downregulating EMT-related transcription factors (TWIST, SLUG, and Zeb1) and reducing angiogenic markers such as VEGF and MMPs. Notably, RV induced autophagy in a dose- and time-dependent manner, as evidenced by increased LC3-II, Beclin1, and p62 expression. In cisplatin-resistant oral cancer models, RV promoted both apoptotic and autophagic cell death, suggesting its potential as an adjuvant therapy. Conclusion This systematic review underscored the potential of RV as a promising anticancer agent for oral cancer. Through apoptosis induction, metastasis suppression, autophagy modulation, and immune regulation, RV demonstrated broad-spectrum anticancer effects. However, its low bioavailability remains a significant challenge. Future research should focus on optimizing drug delivery strategies, such as nanoparticle formulations and combination therapies, to enhance RV’s therapeutic efficacy and facilitate clinical translation.